Let’s start up with the current stock price of Ocular Therapeutix Inc. (OCUL), which is $3.90 to be very precise. The Stock rose vividly during the last session to $4.12 after opening rate of $4.12 while the lowest price it went was recorded $3.845 before closing at $4.10.Recently in News on January 6, 2023, Ocular Therapeutix™ Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones. Dextenza® Net Product Revenue in the Fourth Quarter of 2022 is Estimated to be $13.6 million, Growing Approximately 14% Over Previous Quarter and Approximately 11% Over Same Quarter of Prior Year. You can read further details here
Ocular Therapeutix Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $4.22 on 01/17/23, with the lowest value was $2.77 for the same time period, recorded on 01/03/23.
Ocular Therapeutix Inc. (OCUL) full year performance was -30.97%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Ocular Therapeutix Inc. shares are logging -40.23% during the 52-week period from high price, and 51.75% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $2.57 and $6.53.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 669384 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Ocular Therapeutix Inc. (OCUL) recorded performance in the market was 38.79%, having the revenues showcasing 2.63% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 301.08M, as it employees total of 228 workers.
The Analysts eye on Ocular Therapeutix Inc. (OCUL)
During the last month, 0 analysts gave the Ocular Therapeutix Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 3.87, with a change in the price was noted -1.22. In a similar fashion, Ocular Therapeutix Inc. posted a movement of -23.83% for the period of last 100 days, recording 792,831 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for OCUL is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 1.15.
Technical rundown of Ocular Therapeutix Inc. (OCUL)
Raw Stochastic average of Ocular Therapeutix Inc. in the period of last 50 days is set at 80.61%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 80.37%. In the last 20 days, the company’s Stochastic %K was 88.77% and its Stochastic %D was recorded 91.71%.
Considering, the past performance of Ocular Therapeutix Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 38.79%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -10.76%, alongside a downfall of -30.97% for the period of the last 12 months. The shares increased approximately by -2.50% in the 7-day charts and went down by 41.30% in the period of the last 30 days. Common stock shares were driven by 2.63% during last recorded quarter.